MyMD announced the merger on November 10, 2020. Akers entered into a definitive merger agreement with MyMD. Upon closing the transaction, the combined company will be named MyMD Pharmaceuticals®, Inc. and will remain listed on the Nasdaq under the new ticker symbol MYMD. Both companies are aligned on the mission to solve global health challenges. The merger will continue stimulating the growth already underway, as we advance our promising drug candidates through clinical trials.
